Menopausal hormone therapy is known to increase the risk of cardiovascular disease (CVD). However, the association between the routes of administration and different formulations of new hormone therapy products and CVD risk remains unclear. A recent Swedish study has investigated this association on 919,614 women aged 50-58 without a prior history of hormone therapy. The study found that initiating tibolone was associated with an increased risk of CVD (hazard ratio [HR] – 1.52 compared to non-initiators.
Similarly, the initiation of tibolone or oral estrogen-progestin therapy increased the risk of ischemic heart disease (HR – 1.46 and HR – 1.21, respectively). Furthermore, oral continuous estrogen-progestin therapy, sequential therapy, and estrogen-only therapy increased the risk of venous thromboembolism. Additionally, tibolone use was linked to an elevated risk of cerebral infarction…
